Novo Nordisk (NVO) has cemented itself as the leader in the booming weight-loss drug market with blockbuster treatments like ...

The Cleveland Clinic found in a September report that individuals with a version of the gene Neurobeachin were more likely to ...

Both companies have significant upside and offer robust dividend programs. Even so, Apple rebounded over the past few months, ...

Should the weight-loss pioneers be bracing for more lean years, then? Not necessarily. For although being first did not ...

Morgan Stanley downgraded Novo Nordisk to underweight from equal-weight saying it sees slowing growth of its lucrative GLP-1 ...

Eli Lilly’s valuation has compressed significantly from last year’s highs, despite improving fundamentals. See why I rate LLY ...

Metsera's experimental obesity drug showed significant weight loss and favorable tolerability in two mid-stage studies, the drug developer said on Monday. The injectable drug, MET-097i, led to a ...

With companies racing to secure GLP-1-related assets, there may be risks for moving too fast.

Despite importing popular drugs like Zepbound and Mounjaro, Eli Lilly is exempt from Trump's tariffs on Big Pharma for now.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

CVS Health subsidiary Omnicare has filed for Chapter 11 bankruptcy in the U.S. Bankruptcy Court for the Northern District of Texas. The filing follows both broader financial difficulties and a July ...

Eli Lilly’s (LLY) weight-loss medications may have benefits for people suffering from Alzheimer’s disease, according to new ...